Nafuredin A
Nafuredin A is a trinorsesquiterpene and polyketide derivative found in the mangrove sediment-derived fungi Talaromyces sp. SCSIO 41412 and Trichoderma harzianum D13. Nafuredin A regulates the ferroptosis pathway and upregulates ferroptosis-related genes. Nafuredin A alleviates hypoxia-reoxygenation-induced injury in oxygen-glucose deprivation/reperfusion cell models. Nafuredin A reduces pro-inflammatory cytokines and exerts hepatoprotective effects in animal models of hepatic ischemia-reperfusion injury. Nafuredin A inhibits the growth of phytopathogenic fungi Magnaporthe oryzae and Valsa mali. Nafuredin A can be used in studies related to hepatic ischemia-reperfusion injury and phytopathogenic fungal infections.
For research use only. We do not sell to patients.
- CAS No.: 224427-79-6
- Formula: C22H32O4
- Molecular Weight:360.49
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Nafuredin A (compound 3) (200-400 µM; 24 h) exhibits extremely low cytotoxicity against HepG2 cells at 200 µM, with an IC50 value of 303.6 µM[1].
Nafuredin A (200 µM; 24 h) enriches the ferroptosis pathway and upregulates ferroptosis-related genes NRF2, SLC7A11, FTH1, HMOX1, GCLC and GCLM when applied to HepG2 cells[1].
Nafuredin A (2.5-10 µM; 24 h pre-incubation) significantly reduces OGD/R-induced cytotoxicity in AML12 cells in a concentration-dependent manner[1].
Nafuredin A (compound 2) inhibits the growth of Magnaporthe oryzae with an MIC of 17.4 μM, inhibits Valsa mali with an MIC of 16.7 μM, and shows no activity against Pestallozzia theae[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human hepatocellular carcinoma HepG2 cells
-
Concentration:200, 267, 300, 333, 367, 400 µM
-
Incubation Time:24 h
-
Result:Showed minimal toxicity to HepG2 cells at 200 µM.
-
Cell Line:human hepatocellular carcinoma HepG2 cells
-
Concentration:100 µM
-
Incubation Time:24 h
-
Result:Robustly upregulated core ferroptosis regulatory genes: NRF2, SLC7A11, FTH1, HMOX1, GCLC, and GCLM.
-
Cell Line:mouse hepatocyte AML12 cells
-
Concentration:2.5, 5, 10 µM
-
Incubation Time:24 h (pre-incubation)
-
Result:Significantly attenuated OGD/R-induced cytotoxicity in a concentration-dependent manner.
Restored cellular viability.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 6-8 weeks old, 20-23 g, hepatic ischemia-reperfusion injury model)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; daily; 3 days
-
Result:Lowered serum ALT and AST levels by no less than 45% versus untreated groups.
Cut serum IL-1β content and hepatic IL-1β/IL-18 mRNA expression prominently.
Alleviated HIRI-triggered liver injury via relieving nuclear pyknosis, recovering sinusoidal endothelial integrity and rearranging hepatic cords.
Chemical Information
-
CAS No. 224427-79-6
-
Molecular Weight 360.49
-
Formula C22H32O4
-
SMILES
C[C@@]12[C@@]([C@H](C(O[C@@H]2/C=C/C=C/[C@H](C)C/C(C)=C/C=C/[C@@H](C)CC)=O)O)([H])O1
-
Structure Classification
-
Initial Source
Talaromyces aculeatus and amangrove-derived fungus Penicillium variabile
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz